Last reviewed · How we verify
NCT06733961
SCUBE-1 and VAP-1 Levels on Diagnosis Pulmonary Embolism
trial testing SCUBE-1 and VAP-1 in Pulmonary Embolism Acute in 88 participants. Completed in 30 June 2019.
30 June 2019
Quick facts
| Lead sponsor | Giresun University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 1 January 2019 |
| Primary completion | 30 June 2019 |
| Estimated completion | 30 June 2019 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- SCUBE-1 and VAP-1
Conditions studied
- Pulmonary Embolism Acute — all drugs for Pulmonary Embolism Acute →
Sponsor
Giresun University
Who can join
18 and older, any sex, with Pulmonary Embolism Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute pulmonary thromboembolism is a life-threatening disease. Clinical suspicion is essential for diagnosis because of lack of a specific finding for diagnosis of PTE. The aim of this study is to investigate the relationship between the diagnosis and prognosis of alternative biomarkers such as SCUBE-1 and VAP-1 in the diagnosis of clinically suspected acute PTE. Patients who were admitted to the Emergency Department and diagnosed as acute PTE were included in the study. Patients with acute ischemic disease, liver failure, renal failure, pregnancy, active malignancy and/or history of known PTE were excluded from the study. A control group was formed from healthy volunteers at similar age and sex. SCUBE-1 and VAP-1 levels were studied from serum samples taken from the patient and control groups. Data were analyzed using by IBM SPSS V23.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06733961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Embolism Acute
Currently open trials in the same condition.
- NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
- NCT07436702 — Optimal Time for Reperfusion in Acute Pulmonary Embolism · recruiting
- NCT06152341 — Safety and Effectiveness of the ATC System in the Treatment of Acute PE · NA · recruiting
- NCT07029841 — Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong · recruiting
- NCT06348459 — Registry of Catheter Intervention in Pulmonary Embolism · recruiting
Other Giresun University trials
Trials by the same sponsor.
- NCT07520916 — The Effect of Mobile-Based Perioperative Education on Urinary Incontinence and Erectile Function After Radical Prostatec · NA · recruiting
- NCT07401914 — Ketodex Versus Ketofol in Adolescent Gastrointestinal Endoscopy · not yet recruiting
- NCT07401927 — Preemptive Analgesia in Laparoscopic Hysterectomy · not yet recruiting
- NCT07283172 — The Effect of Virtual Reality · NA · not yet recruiting
- NCT07427147 — CULTURAL SENSITIVITY TRAINING · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06733961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Giresun University
- Last refreshed: 13 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06733961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing